Walgreens Boots Alliance (NASDAQ:WBA – Get Free Report) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 1.400-1.800 for the period, compared to the consensus earnings per share estimate of 1.520. The company issued revenue guidance of -.
Wall Street Analysts Forecast Growth
A number of analysts recently commented on WBA shares. TD Cowen dropped their price target on shares of Walgreens Boots Alliance from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, October 22nd. Royal Bank of Canada dropped their target price on Walgreens Boots Alliance from $13.00 to $9.00 and set a “sector perform” rating on the stock in a research report on Wednesday, December 4th. Barclays lifted their price target on Walgreens Boots Alliance from $7.00 to $8.00 and gave the company an “underweight” rating in a research report on Wednesday, October 16th. Evercore ISI increased their price objective on Walgreens Boots Alliance from $7.50 to $10.00 and gave the stock an “in-line” rating in a report on Wednesday, October 16th. Finally, UBS Group lifted their target price on Walgreens Boots Alliance from $9.00 to $10.00 and gave the company a “neutral” rating in a report on Thursday, October 17th. Four research analysts have rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Walgreens Boots Alliance currently has a consensus rating of “Hold” and an average target price of $12.58.
Check Out Our Latest Stock Report on WBA
Walgreens Boots Alliance Price Performance
Walgreens Boots Alliance (NASDAQ:WBA – Get Free Report) last issued its earnings results on Tuesday, October 15th. The pharmacy operator reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.03. The business had revenue of $37.50 billion during the quarter, compared to analyst estimates of $35.75 billion. Walgreens Boots Alliance had a positive return on equity of 14.23% and a negative net margin of 5.85%. Walgreens Boots Alliance’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.67 earnings per share. On average, equities research analysts anticipate that Walgreens Boots Alliance will post 1.53 earnings per share for the current fiscal year.
Walgreens Boots Alliance Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Thursday, December 12th. Shareholders of record on Monday, November 18th were paid a $0.25 dividend. This represents a $1.00 annualized dividend and a yield of 10.85%. The ex-dividend date of this dividend was Monday, November 18th. Walgreens Boots Alliance’s dividend payout ratio is presently -9.99%.
Walgreens Boots Alliance Company Profile
Walgreens Boots Alliance, Inc operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.
Read More
- Five stocks we like better than Walgreens Boots Alliance
- Most active stocks: Dollar volume vs share volume
- Unstoppable Yields: 3 Blue-Chip Stocks to Maximize Returns
- What Are the U.K. Market Holidays? How to Invest and Trade
- Is Domino’s Recent Dip a Recipe for Long-Term Gains?
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- EV Sales Are Hitting Record Highs: 3 ETFs That Can Benefit
Receive News & Ratings for Walgreens Boots Alliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance and related companies with MarketBeat.com's FREE daily email newsletter.